Hancock Jaffe Laboratories, Inc. (HJLI) News
Filter HJLI News Items
HJLI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HJLI News Highlights
- HJLI's 30 day story count now stands at 6.
- Over the past 24 days, the trend for HJLI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest HJLI News From Around the Web
Below are the latest news stories about Hancock Jaffe Laboratories Inc that investors may wish to consider to help them evaluate HJLI as an investment opportunity.
enVVeno Medical Corporation Successfully Completes RebrandingCompany Now Trading Under Ticker Symbol "NVNO"IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe Laboratories, Inc. |
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg ThalmannLive webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe LaboratoriesIRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate in The Duologue Series hosted by Ladenburg Thalmann |
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs\- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -\- Development strategy to focus on venous disease and advancement of the VenoValve® -\- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -\- Management to host a conference call with live video webcast at 4:30 p. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratorie |
Multiple insiders bought Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) stock earlier this year, a positive sign for shareholdersGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. |
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ RulesIRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules. |
Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency ValveHancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting. The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement). Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement). Pain decreased from an average of 7.25 to an average of .50 (an improvement |
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual MeetingTwo-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectivelyPatients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrencesNo safety issues occurred during the one-year reporting period following the study completionIRVINE, CA / ACCESSWIRE / August 19, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac |
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve\- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions\- Company preparing to begin SAVVE U. pivotal trial for VenoValve\- VenoValve is a potential treatment for approximately 2. |
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare ConferenceLive webcast on Tuesday, July 13th at 1:00 PM ETIRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Robert Berman, CEO of Hancock Jaffe will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021 at 1:00 PM ET. |